Adobe and Antom Forge Strategic Partnership to Empower Digital Creativity with Seamless Payment Access Across Asia
Adobe and Antom, a leading provider of unified merchant payments and digitisation solutions under Ant International, today announced a strategic partnership to launch an optimized payment experience and tailored digital marketing offerings for Adobe’s customers across Asia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250414876555/en/
After selecting products on Adobe.com, customers will be able to choose a preferred payment option at checkout, enjoying a more tailored payment experience.
“At Adobe, we’re always looking to deliver elevated and localized experiences for our customers. As our base of customers in Asia fast expands, we’re excited to announce our partnership with Antom to integrate localized payment options for our customers and unlock new growth opportunities in the various markets we’re expanding with Antom into,” said Matt Wegner, Vice President, Global Payments, at Adobe.
Adobe will integrate localized payment solutions to strengthen its global footprint with its user-centric approach. Leveraging Antom's comprehensive acquiring network, advanced payment technology and broad local payment method coverage across Asia, this partnership will help Adobe optimize transaction flows, increasing conversion rates, and ensuring fast, secure and cost-effective payment settlement.
In the first phase of the collaboration, 8 new alternative payment options will be rolled out across 8 key Asian markets, including AlipayHK (Hong Kong SAR, China), DANA (Indonesia), GCash (the Philippines), Kakao Pay (South Korea), Momo (Vietnam), PayPay (Japan), Touch ‘n Go (Malaysia) and True Money (Thailand). Moving forward, both companies may explore opportunities to introduce additional payment methods to include credit cards, bank transfers, digital wallets, and more.
"We are excited to collaborate with Adobe, a pioneer in leveraging AI to enhance creativity and productivity for its users. Through this partnership, we aim to make Adobe's advanced tools more accessible to a broader customer base in high-growth markets. Adobe's AI strategy aligns closely with our commitment to supporting merchants with unified payment solutions powered by AI, and we look forward to driving greater synergy together," said Gary Liu, General Manager of Antom, Ant International.
Beyond payments, the two parties will explore opportunities to introduce Adobe into Antom’s A+ Rewards, an in-App digital marketing platform powered by privacy-preserving computing and AI technologies. It connects brands with hundreds of millions of e-wallet users by embedding with leading e-wallets in Asia. This collaboration is expected to help Adobe improve customer acquisition and engagement through targeted campaigns integrated into users’ everyday digital payment experiences.
“We work with global industry leaders to enhance their presence and advance digital innovations in Asia and beyond, and the partnership with Adobe is part of that effort. We look forward to enabling professionals and enterprises, especially small businesses, to adopt cutting-edge technology and fully unlock their potential," Liu added.
Overall, the Antom-Adobe partnership will enhance accessibility to creative professionals, businesses and educational institutions, helping them leverage Adobe’s products with greater flexibility. Region-specific payment options built on Antom’s robust payment infrastructure will allow Adobe to respond to the evolving needs of customers in the Asia market via an omnichannel marketing approach that will deploy curated offers and content that is supported by their most preferred payment methods.
About Antom
Ant International's Antom is the leading payment and digitisation services provider for merchants around the world. It offers unified, vertical-specific digital payment solutions to serve businesses of all sizes. Antom supports merchants in over 50 countries and regions, enabling them to connect with consumers in more than 200 markets, with the flexibility to accept payments in more than 100 currencies. Beyond payments, it provides digital marketing solutions and merchant digitisation services to help merchant streamline operations and enhance customer engagement. To learn more, please visit https://www.antom.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250414876555/en/
Contacts
Media Contact
Ant International
Janice Chen
janicechen.cyh@antgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom